Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now Frankfurt - Delayed Quote • EUR Haemonetics Corporation (HAZ.F) Follow Compare 54.50 -1.50 (-2.68%) At close: April 4 at 9:39:52 PM GMT+2 All News Press Releases SEC Filings Q4 Earnings Highs And Lows: Haemonetics (NYSE:HAE) Vs The Rest Of The Medical Devices & Supplies - Specialty Stocks Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Haemonetics (NYSE:HAE) and the best and worst performers in the medical devices & supplies - specialty industry. 3 Reasons to Avoid HAE and 1 Stock to Buy Instead Haemonetics has gotten torched over the last six months - since October 2024, its stock price has dropped 20.1% to $63.39 per share. This was partly due to its softer quarterly results and might have investors contemplating their next move. Haemonetics Corp. (HAE): Among the 10 Pro-Life Companies to Invest In Now? We recently published a list of 10 Pro-Life Companies to Invest In Now. In this article, we are going to take a look at where Haemonetics Corporation (NYSE:HAE) stands against other top pro-life companies to invest in now. Investing isn’t just about numbers—it’s also about values. As socially responsible investing (SRI) gains traction, a growing […] Haemonetics Sets Date for Publishing Fourth Quarter and Fiscal Year 2025 Results: May 8, 2025 Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish fourth quarter and fiscal year 2025 financial results at 6:00 am ET on Thursday, May 8, 2025. The Company will hold a conference call with investors and analysts to discuss results and answer questions at 8:00 am ET on May 8, 2025. A Note On Haemonetics Corporation's (NYSE:HAE) ROE and Debt To Equity Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is... Medtronic (MDT) Up 5.6% Since Last Earnings Report: Can It Continue? Medtronic (MDT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. 3 Healthcare Stocks Walking a Fine Line From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But speed bumps such as inventory destockings have persisted in the wake of COVID-19, and over the past six months, the industry has pulled back by 8.4%. This drop was disappointing since the S&P 500 stood firm. Is it Apt to Retain HAE Stock in Your Portfolio for Now? Strong prospects for the Hospital Business and the robust NexSys PCS system bode well for Haemonetics. Medical Devices & Supplies - Specialty Stocks Q4 In Review: Globus Medical (NYSE:GMED) Vs Peers Looking back on medical devices & supplies - specialty stocks’ Q4 earnings, we examine this quarter’s best and worst performers, including Globus Medical (NYSE:GMED) and its peers. Haemonetics Announces Executive Leadership Updates Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative medical solutions to drive better patient outcomes, today announced updates to its Executive Leadership team. Frank Chan, Ph.D. will join Haemonetics as Executive Vice President, Chief Operating Officer on April 7, 2025, and Roy Galvin has been appointed as the company's Executive Vice President, Chief Commercial Officer effective immediately. A Look Back at Medical Devices & Supplies - Specialty Stocks’ Q3 Earnings: STAAR Surgical (NASDAQ:STAA) Vs The Rest Of The Pack Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at STAAR Surgical (NASDAQ:STAA) and the best and worst performers in the medical devices & supplies - specialty industry. US Stocks That May Be Trading At A Discount In February 2025 As February 2025 unfolds, the U.S. stock market is experiencing a notable downturn, with major indices like the S&P 500 and Nasdaq Composite extending their slump amid significant declines in technology shares. In this climate of uncertainty, investors may find opportunities in stocks that are potentially undervalued, offering a chance to buy at a discount as market volatility continues to shape investment decisions. Haemonetics to Present at Raymond James 46th Annual Institutional Investors Conference Haemonetics Corporation (NYSE: HAE) announced that Chris Simon, President and CEO, will participate in a fireside chat with investors at the Raymond James 46th Annual Institutional Investors Conference on Tuesday, March 4, 2025 at 2:50 p.m. ET. Haemonetics' (NYSE:HAE) Earnings Offer More Than Meets The Eye The market seemed underwhelmed by the solid earnings posted by Haemonetics Corporation ( NYSE:HAE ) recently. We have... Inspire Medical Systems (INSP) To Report Earnings Tomorrow: Here Is What To Expect Medical technology company Inspire Medical Systems (NYSE:INSP) will be reporting results tomorrow after market close. Here’s what you need to know. HAE Q3 Earnings In Line, '25 Sales View Cut, Stock Up in Aftermarket Haemonetics' third-quarter fiscal 2025 results reflect the positive effects of the company's long-range plan with meaningful earnings growth and margin expansion. Haemonetics Third Quarter 2025 Earnings: Misses Expectations Haemonetics ( NYSE:HAE ) Third Quarter 2025 Results Key Financial Results Revenue: US$348.5m (up 3.7% from 3Q 2024... Haemonetics Corp (HAE) Q3 2025 Earnings Call Highlights: Strong Hospital Growth Amid Plasma ... Haemonetics Corp (HAE) reports robust earnings with a 14% EPS increase, despite facing hurdles in the plasma and hemostasis management segments. Haemonetics (HAE) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates Although the revenue and EPS for Haemonetics (HAE) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. Haemonetics (HAE) Q3 Earnings Meet Estimates Haemonetics (HAE) delivered earnings and revenue surprises of 0% and 1.30%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock? Performance Overview Trailing total returns as of 4/4/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) Return HAZ.F S&P 500 (^GSPC) YTD -27.81% -13.73% 1-Year -30.13% -1.42% 3-Year -4.39% +10.72%